Vancouver Prostate Centre investigators were highly successful, receiving 6 Canadian Institutes of Health Research (CIHR) research grants in the Fall 2017 Project Grant competition for a total of $3.48 million over five years.
The funded projects are:
- Ralph Buttyan (co-Is: Artem Cherkasov, Nathan Lack, Na Li): Interference with Gli to Control Castration Resistant Prostate Cancer. 3 years. $344,250
Read the original VCHRI News story here.
Dr. Martin Gleave was recently named a member of the Order of Canada, one of the country’s highest civilian honours, for his leadership role in developing new treatments for prostate cancer and for his research on the mechanisms involved in the development of treatment resistance in cancer.
Dr. Alex Wyatt has been awarded a CIHR Early Career Investigator Award for $345,000 over 3 years. His project aims to develop a procedure that will enable the identification of metastatic bladder cancer patients most likely to respond to specific therapies.
Federal Minister of Justice and Attorney General of Canada Jody Wilson-Raybould today announced UBC's successful CFI Infrastructure Fund awardees. The largest grant, $9 million, was awarded to a research program led by Dr. Artem Cherkasov, titled Accelerated Drug Discovery Using Clinical Translation (ADDUCT).
Thee publications out of the VPC describing work towards the development of new therapeutics were published in the last week.
The results of research awards from two agencies today demonstrate the VPC's successful translation of basic research into discoveries that are moving to clinical applications.
July 26, 2017 - TORONTO, ON - Continuing their longstanding tradition of partnering to fund high quality Canadian prostate cancer research, Prostate Cancer Canada (PCC) and The Movember Foundation today announced two new projects with very real potential to make a tangible difference in the lives of men living with aggressive forms of prostate cancer.
The Best of the AACR Journals collection 2016 highlights the most-cited articles published in 2015 across the AACR journals.
The Journal of the National Cancer Institute today published a landmark multi-institutional study describing the first comprehensive comparison of blood-based tumour biopsy versus metastatic tissue biopsy for lethal prostate cancer.